AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans

AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed cashed in on a stock surge and Third Harmonic kicked off a drug auction. 

By Ben Fidler • June 13, 2025

SpliceBio lands $135M for a new kind of eye gene therapy

The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to help overcome the packaging constraints of current genetic medicines.

By Gwendolyn Wu • June 11, 2025

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

Insmed surges on lung drug data; Recursion cuts staff

Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations. Elsewhere, Recursion is laying off 20% of its workforce and Gilead halted several HIV studies.

By BioPharma Dive staff • June 11, 2025

FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche

The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already struggled to grow sales.

By Ben Fidler • June 11, 2025

Scorpion, fresh off Lilly deal, spins out startup Antares

Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its former management team to chase “previously inaccessible” drug targets. 

By Ben Fidler • June 10, 2025

National Resilience, a well-funded manufacturing startup, to scale back operations

The startup, which has raised more than $2 billion in funding to aid young biotechs with drug production, said its “capacity expansion has outpaced industry demand.”

By Gwendolyn Wu • June 10, 2025

Concentra to acquire Elevation in bid to eliminate another biotech ‘zombie’

The offer is the latest in a series of deals by Concentra, an entity controlled by Tang Capital Partners, to buy struggling biotechs and shut them down. 

By Ben Fidler • June 9, 2025

Metsera shares climb on early data for amylin-targeting obesity shot

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, might have effects that last at least four weeks.

By Jonathan Gardner • Updated June 9, 2025

Omada goes public in second recent digital health IPO

The chronic condition management company’s debut comes weeks after another digital health company, Hinge Health, went public. The IPOs are a “promising bellwether” for the sector, one expert said.

By Emily Olsen • June 9, 2025

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update

Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized Regenxbio’s Duchenne data and a brain drug study failed.

By BioPharma Dive staff • June 6, 2025

Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal

The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for antibody- and cell-based drugs for inflammatory conditions.

By Kristin Jensen • June 5, 2025

Biotech funding plummets as Trump policies unnerve investors: Jefferies

The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA restructuring, NIH cuts and drug pricing rules are “exacerbating” the decline.

By Jacob Bell • June 4, 2025

Regeneron makes obesity push; Atai, Alto ink brain drug deals

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

By BioPharma Dive staff • June 4, 2025

Kymera, with new data, takes early step toward a Dupixent-like pill

Phase 1 results disclosed Monday indicate the company’s protein-degrading drug can affect a tough-to-reach target called STAT6 that’s implicated in many autoimmune conditions.  

By Gwendolyn Wu • June 2, 2025

Vera drug scores in closely watched study in rare kidney disease

Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a competitive corner of drug research, later this year. 

By Ben Fidler • June 2, 2025

Bristol Myers allies with BioNTech on bispecific cancer drug

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following Merck and Pfizer into what’s become a competitive development race. 

By Ned Pagliarulo • June 2, 2025

Genetics is a missing link in kidney disease drug development

Genetic research is driving progress in kidney disease drug discovery.

June 2, 2025

New Summit data could slow US approval plans for PD-1/VEGF drug

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly extended survival, which will be necessary to support an FDA submission.

By Ben Fidler • May 30, 2025

Keros lays off nearly half its staff; Astellas buys into a China biotech’s ADC

Keros will also stop work on a cardiovascular disease drug. Elsewhere, Stealth Biotherapeutics and Taysha Gene Therapies each think they've found a path to FDA approval.

By BioPharma Dive staff • May 30, 2025

HHS terminates Moderna contract to develop bird flu vaccine

The funding was meant to help the U.S. prepare for pandemics triggered by avian flu strains, but now leaves the future of Moderna’s program uncertain. 

By Delilah Alvarado • May 29, 2025

Intellia filing spurs safety concerns over CRISPR drug

Shares lost a quarter of their value after the company disclosed, in a regulatory filing, signs of liver stress in a study participant given one of its gene editing treatments. 

By Kristin Jensen • May 29, 2025

The medtech IPO window is finally open. Or is it?

After a three-year drought, the industry is questioning whether the window for medtech public offerings is open following a small burst of activity.

By Ricky Zipp • May 29, 2025

Cancer drugmaker iTeos to shut down

Weeks after shelving a TIGIT drug prospect, the biotech is seeking to sell off its assets and intellectual property in a bid to "maximize" shareholder value.

By Gwendolyn Wu • May 28, 2025

Muscle-sparing obesity drug safe for Phase 3 trial, Veru says

The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

By Jonathan Gardner • May 28, 2025

[Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care

Agile biopharma firms are driving breakthroughs. Learn how they ensure clinical trial success in this podcast.

By BioPharma Dive's studioID • May 28, 2025